Asia Pacific Active Pharmaceutical Ingredients (API) Market 2022-2032 by Molecule (Small, Large), Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

April 2023 | 196 pages | ID: A2B0A572318EEN
GMD Research

Abstracts

Asia Pacific active pharmaceutical ingredients (API) market will grow by 8.1% annually with a total addressable market cap of $ 1,098.6 billion over 2023-2032, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population.

Highlighted with 88 tables and 75 figures, this 196-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2022-2032 by Molecule (Small, Large), Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific active pharmaceutical ingredients (API) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific active pharmaceutical ingredients (API) market in every aspect of the classification from perspectives of Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Molecule, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Small Molecule APIs
• Large Molecule APIs

Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Synthetic API
• Branded Synthetic API
• Generic Synthetic API
• Biotech API
• by type
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
• by Category
• Innovative Biologic API
• Generic Biosimilar API
• by Expression
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
• HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Captive Manufacturing
• Branded Captive API
• Generic Captive API
• Merchant Manufacturing
• by Drug Type
• Branded Merchant API
• Generic Merchant API
• by Drug Synthesis
• Merchant Synthetic API
• Merchant Biotech API

By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:

• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

AbbVie Inc.

Astrazeneca

Aurobindo Pharma Ltd.

BASF

Bayer AG

Boehringer Ingelheim

Catalent Inc.

Dr. Reddy's Laboratories

F. Hoffmann-La Roche

GlaxoSmithKline plc

Lonza Group

Lupin Limited

Merck & Co., Inc.

Mylan NV

Novartis International AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Thermo Fisher Scientific

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
  2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY MOLECULE

3.1 Market Overview by Molecule
3.2 Small Molecule APIs
3.3 Large Molecule APIs

4 SEGMENTATION OF ASIA PACIFIC MARKET BY SYNTHESIS

4.1 Market Overview by Synthesis
4.2 Synthetic API
  4.2.1 Branded Synthetic API
  4.2.2 Generic Synthetic API
4.3 Biotech API
  4.3.1 Biotech API by Drug Type
    4.3.1.1 Monoclonal Antibodies
    4.3.1.2 Recombinant Proteins
    4.3.1.3 Vaccines
    4.3.1.4 Other Biotech APIs
  4.3.2 Biotech API by Category
    4.3.2.1 Innovative Biologic API
    4.3.2.2 Generic Biosimilar API
  4.3.3 Biotech API by Expression Technology
    4.3.3.1 Mammalian Expression
    4.3.3.2 Microbial Expression
    4.3.3.3 Yeast Expression
    4.3.3.4 Insect Expression
    4.3.3.5 Other Expression Technologies
4.4 HPAPI
  4.4.1 Branded HPAPI
  4.4.2 Generic HPAPI

5 SEGMENTATION OF ASIA PACIFIC MARKET BY MANUFACTURING PROCESS

5.1 Market Overview by Manufacturing Process
5.2 Captive Manufacturing
  5.2.1 Branded Captive API
  5.2.2 Generic Captive API
5.3 Merchant Manufacturing
  5.3.1 Merchant Manufacturing by Drug Type
    5.3.1.1 Branded Merchant API
    5.3.1.2 Generic Merchant API
  5.3.2 Merchant Manufacturing by Drug Synthesis
    5.3.2.1 Merchant Synthetic API
    5.3.2.2 Merchant Biotech API

6 SEGMENTATION OF ASIA PACIFIC MARKET BY THERAPEUTIC APPLICATION

6.1 Market Overview by Therapeutic Application
6.2 Infectious Diseases
6.3 Oncology
6.4 Ophthalmology
6.5 Cardiovascular Disorders
6.6 Central Nervous System
6.7 Pulmonary Disorders
6.8 Orthopedics
6.9 Other Applications

7 SEGMENTATION OF ASIA PACIFIC MARKET BY DRUG TYPE

7.1 Market Overview by Drug Type
7.2 Branded Prescription Drugs
7.3 Generic Prescription Drugs
7.4 OTC Drugs

8 ASIA-PACIFIC MARKET 2022-2032 BY COUNTRY

8.1 Overview of Asia-Pacific Market
8.2 China
8.3 Japan
8.4 India
8.5 Australia
8.6 South Korea
8.7 Rest of APAC Region

9 COMPETITIVE LANDSCAPE

9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
Related Reports and Products

List Of Tables

LIST OF TABLES:

Table 1. Snapshot of Asia Pacific Active Pharmaceutical Ingredients (API) Market in Balanced Perspective, 2022-2032
Table 2. World Economic Outlook, 2021-2031
Table 3. World Economic Outlook, 2021-2023
Table 4. Scenarios for Economic Impact of Ukraine Crisis
Table 5. World Health Spending by Region, $ bn, 2013-2020
Table 6. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn
Table 7. Main Product Trends and Market Opportunities in Asia Pacific Active Pharmaceutical Ingredients (API) Market
Table 8. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, $ bn
Table 9. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn
Table 10. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2022-2032, $ bn
Table 11. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2022-2032, $ bn
Table 12. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Category, 2022-2032, $ bn
Table 13. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2022-2032, $ bn
Table 14. Asia Pacific Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2022-2032, $ bn
Table 15. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn
Table 16. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2022-2032, $ bn
Table 17. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2022-2032, $ bn
Table 18. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2022-2032, $ bn
Table 19. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn
Table 20. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, $ bn
Table 21. APAC Active Pharmaceutical Ingredients (API) Market by Country, 2022-2032, $ bn
Table 22. China Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn
Table 23. China Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn
Table 24. China Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn
Table 25. Japan Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn
Table 26. Japan Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn
Table 27. Japan Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn
Table 28. India Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn
Table 29. India Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn
Table 30. India Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn
Table 31. Australia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn
Table 32. Australia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn
Table 33. Australia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn
Table 34. South Korea Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, $ bn
Table 35. South Korea Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, $ bn
Table 36. South Korea Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, $ bn
Table 37. Active Pharmaceutical Ingredients (API) Market in Rest of APAC by Country, 2022-2032, $ bn
Table 38. AbbVie Inc.: Company Snapshot
Table 39. AbbVie Inc.: Business Segmentation
Table 40. AbbVie Inc.: Product Portfolio
Table 41. Astrazeneca: Company Snapshot
Table 42. Aurobindo Pharma Ltd.: Company Snapshot
Table 43. Aurobindo Pharma Ltd.: Product Portfolio
Table 44. BASF: Company Snapshot
Table 45. BASF: Business Segmentation
Table 46. Bayer AG: Company Snapshot
Table 47. Bayer AG: Business Segmentation
Table 48. Bayer AG: Product Portfolio
Table 49. Boehringer Ingelheim: Company Snapshot
Table 50. Boehringer Ingelheim: Product Portfolio
Table 51. Catalent Inc.: Company Snapshot
Table 52. Catalent Inc.: Business Segmentation
Table 53. Catalent Inc.: Product Portfolio
Table 54. Dr. Reddy's Laboratories: Company Snapshot
Table 55. Dr. Reddy's Laboratories: Business Segmentation
Table 56. F. Hoffmann-La Roche: Company Snapshot
Table 57. F. Hoffmann-La Roche: Clinical Trial Service
Table 58. F. Hoffmann-La Roche: Business Segmentation
Table 59. F. Hoffmann-La Roche: Revenue by Region
Table 60. GlaxoSmithKline: Company Snapshot
Table 61. GlaxoSmithKline: Business Segmentation
Table 62. GlaxoSmithKline: Product Portfolio
Table 63. Lonza Group: Company Snapshot
Table 64. Lonza Group: Business Segmentation
Table 65. Lonza Group: Product Portfolio
Table 66. Lupin Limited: Company Snapshot
Table 67. Lupin Limited: Business Segmentation
Table 68. Merck & Co., Inc.: Company Snapshot
Table 69. Merck & Co., Inc.: Business Segmentation
Table 70. Mylan NV: Company Snapshot
Table 71. Mylan NV: Breakdown of Revenue by Region, 2022
Table 72. Mylan NV: Breakdown of Revenue by Product Category, 2022
Table 73. Novartis International AG: Company Snapshot
Table 74. Novartis International AG: Business Segmentation
Table 75. Pfizer Inc.: Company Snapshot
Table 76. Pfizer Inc.: Business Segmentation
Table 77. Pfizer Inc.: Breakdown of Revenue by Product Category
Table 78. Pfizer Inc.: Breakdown of Revenue by Region
Table 79. Pfizer Inc.: Product Portfolio
Table 80. Sanofi: Company Snapshot
Table 81. Sanofi: Business Segmentation
Table 82. Sanofi: Breakdown of Revenue by Region
Table 83. Sun Pharmaceutical Industries Limited: Company Snapshot
Table 84. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 85. Teva Pharmaceutical Industries Ltd.: Business Segmentation
Table 86. Thermo Fisher Scientific: Company Snapshot
Table 87. Thermo Fisher Scientific: Breakdown of Revenue by Business Segment, 2020, %
Table 88. Thermo Fisher Scientific: Breakdown of Revenue by Region, 2020, %

List Of Figures

LIST OF FIGURES:

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032
Figure 4. Asia Pacific Active Pharmaceutical Ingredients (API) Market, 2022-2032, $ bn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Active Pharmaceutical Ingredients (API) Market
Figure 7. GDP per capita in the World, 1960-2022, $ thousand
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060
Figure 11. Primary Restraints and Impact Factors of Asia Pacific Active Pharmaceutical Ingredients (API) Market
Figure 12. Investment Opportunity Analysis
Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Active Pharmaceutical Ingredients (API) Market
Figure 14. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule, 2022-2032, % of Revenue
Figure 15. Asia Pacific Addressable Market Cap in 2023-2032 by Molecule, Value ($ bn) and Share (%)
Figure 16. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule: Small Molecule APIs, 2022-2032, $ bn
Figure 17. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Molecule: Large Molecule APIs, 2022-2032, $ bn
Figure 18. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2022-2032, % of Revenue
Figure 19. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%)
Figure 20. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis: Synthetic API, 2022-2032, $ bn
Figure 21. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthetic API: Branded Synthetic API, 2022-2032, $ bn
Figure 22. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthetic API: Generic Synthetic API, 2022-2032, $ bn
Figure 23. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis: Biotech API, 2022-2032, $ bn
Figure 24. Asia Pacific Biotech API Market by Drug Type: Monoclonal Antibodies, 2022-2032, $ bn
Figure 25. Asia Pacific Biotech API Market by Drug Type: Recombinant Proteins, 2022-2032, $ bn
Figure 26. Asia Pacific Biotech API Market by Drug Type: Vaccines, 2022-2032, $ bn
Figure 27. Asia Pacific Biotech API Market by Drug Type: Other Biotech APIs, 2022-2032, $ bn
Figure 28. Asia Pacific Biotech API Market by Category: Innovative Biologic API, 2022-2032, $ bn
Figure 29. Asia Pacific Biotech API Market by Category: Generic Biosimilar API, 2022-2032, $ bn
Figure 30. Asia Pacific Biotech API Market by Expression Technology: Mammalian Expression, 2022-2032, $ bn
Figure 31. Asia Pacific Biotech API Market by Expression Technology: Microbial Expression, 2022-2032, $ bn
Figure 32. Asia Pacific Biotech API Market by Expression Technology: Yeast Expression, 2022-2032, $ bn
Figure 33. Asia Pacific Biotech API Market by Expression Technology: Insect Expression, 2022-2032, $ bn
Figure 34. Asia Pacific Biotech API Market by Expression Technology: Other Expression Technologies, 2022-2032, $ bn
Figure 35. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis: HPAPI, 2022-2032, $ bn
Figure 36. Asia Pacific Active Pharmaceutical Ingredients (API) Market by HPAPI: Branded HPAPI, 2022-2032, $ bn
Figure 37. Asia Pacific Active Pharmaceutical Ingredients (API) Market by HPAPI: Generic HPAPI, 2022-2032, $ bn
Figure 38. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2022-2032, % of Revenue
Figure 39. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%)
Figure 40. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Captive Manufacturing, 2022-2032, $ bn
Figure 41. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Branded Captive API, 2022-2032, $ bn
Figure 42. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Captive Manufacturing: Generic Captive API, 2022-2032, $ bn
Figure 43. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process: Merchant Manufacturing, 2022-2032, $ bn
Figure 44. Asia Pacific API Merchant Manufacturing Market by Drug Type: Branded Merchant API, 2022-2032, $ bn
Figure 45. Asia Pacific API Merchant Manufacturing Market by Drug Type: Generic Merchant API, 2022-2032, $ bn
Figure 46. Asia Pacific API Merchant Manufacturing Market by Drug Synthesis: Merchant Synthetic API, 2022-2032, $ bn
Figure 47. Asia Pacific API Merchant Manufacturing Market by Drug Synthesis: Merchant Biotech API, 2022-2032, $ bn
Figure 48. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2022-2032, % of Revenue
Figure 49. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%)
Figure 50. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Infectious Diseases, 2022-2032, $ bn
Figure 51. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Oncology, 2022-2032, $ bn
Figure 52. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Ophthalmology, 2022-2032, $ bn
Figure 53. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Cardiovascular Disorders, 2022-2032, $ bn
Figure 54. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Central Nervous System, 2022-2032, $ bn
Figure 55. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Pulmonary Disorders, 2022-2032, $ bn
Figure 56. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Orthopedics, 2022-2032, $ bn
Figure 57. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application: Other Applications, 2022-2032, $ bn
Figure 58. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2022-2032, % of Revenue
Figure 59. Contribution to Asia Pacific 2023-2032 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%)
Figure 60. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type: Branded Prescription Drugs, 2022-2032, $ bn
Figure 61. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type: Generic Prescription Drugs, 2022-2032, $ bn
Figure 62. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type: OTC Drugs, 2022-2032, $ bn
Figure 63. Breakdown of APAC Active Pharmaceutical Ingredients (API) Market by Country, 2022 and 2032, % of Revenue
Figure 64. Contribution to APAC 2023-2032 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 65. Active Pharmaceutical Ingredients (API) Market in China, 2022-2032, $ bn
Figure 66. Active Pharmaceutical Ingredients (API) Market in Japan, 2022-2032, $ bn
Figure 67. Active Pharmaceutical Ingredients (API) Market in India, 2022-2032, $ bn
Figure 68. Active Pharmaceutical Ingredients (API) Market in Australia, 2022-2032, $ bn
Figure 69. Active Pharmaceutical Ingredients (API) Market in South Korea, 2022-2032, $ bn
Figure 70. Active Pharmaceutical Ingredients (API) Market in Rest of APAC, 2022-2032, $ bn
Figure 71. Growth Stage of Asia Pacific Active Pharmaceutical Ingredients (API) Industry over the Forecast Period
Figure 72. AstraZeneca: Breakdown of Revenue by Therapy Area, 2022
Figure 73. AstraZeneca: Breakdown of Revenue by Region, 2022
Figure 74. Boehringer Ingelheim: Revenue by Business Segment, 2019-2022
Figure 75. Boehringer Ingelheim: R&D Investement, 2019-2022